← All Akari Therapeutics PLC filings

Akari Therapeutics PLC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
AKTX
Akari Therapeutics PLC
DEF: Akari Seeks Shareholder Approval for Warrant Exercises
Akari Therapeutics, Plc is seeking shareholder approval for the exercisability of warrants issued in recent offerings and a note exchange to comply with Nasdaq listing rules.
NASDAQ
AKTX
Akari Therapeutics PLC
DEF: Akari Seeks Shareholder Approval for Warrants, Capital Restructure
Akari Therapeutics calls a General Meeting to approve warrant exercisability and a comprehensive capital restructuring, including a share sub-division and new share allotment authority.
NASDAQ
AKTX
Akari Therapeutics PLC
DEF 14A: Akari Therapeutics Seeks Shareholder Approval for Massive Equity Expansion and Director Compensation Amidst Widening Losses
Akari Therapeutics, Plc is seeking shareholder approval for a significant increase in its equity incentive plan, new share allotment authority, and director stock options, as the company reports a 32% decrease in cash and a near doubling of net losses for the fiscal year ended December 31, 2024.
NASDAQ
AKTX
Akari Therapeutics PLC
DEF 14A: Akari Therapeutics Sets Date for 2024 Annual General Meeting
Akari Therapeutics, Plc will hold its 2024 Annual General Meeting of Shareholders on June 27, 2024, in London.